Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 04, 2015 2:52 PM ET

Pharmaceuticals

Company Overview of ADC Therapeutics Sarl

Company Overview

ADC Therapeutics Sarl develops antibody drug conjugates (ADCs) and non-antibody drug conjugate products. The company is based in Lausanne, Switzerland. ADC Therapeutics Sarl operates as a subsidiary of Celtic Therapeutics Holdings L.P.

Lausanne,  

Switzerland

Key Executives for ADC Therapeutics Sarl

Chief Executive Officer
Co-Founder, Chairman and Managing General Partner of Auven Therapeutics
Age: 67
Director of Finance
Senior Vice President of Research & Development
Chief Medical Officer and Head of Oncology Clinical Development
Compensation as of Fiscal Year 2015.

ADC Therapeutics Sarl Key Developments

ADC Therapeutics Sarl Announces Executive Changes

ADC Therapeutics Sarl announced the appointment of Dr. Chris Martin as its Chief Executive Officer. Dr. Martin was co-founder of Spirogen Ltd. and its Chief Executive Officer. Dr. Martin continued as CEO of Spirogen, and became both a member of Medimmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. Dr. Martin will continue to advise Medimmune as a consultant. Dr. Martin replaces Michael Forer who has served as CEO of the company since its formation. Mr. Forer is a Partner in the private equity firm Auven Therapeutics and was the lead investor on behalf of Auven for its majority investments in both Spirogen Ltd. and ADC Therapeutics. The company also announced that Mr. Forer becomes vice chairman of the company, and will continue to work with the company as executive vice president focused on its public markets capital strategy, business and finance activities.

ADC Therapeutics Submits its First IND for a Novel Antibody Drug Conjugate Against Lymphomas

ADC Therapeutics Sarl announced that it has filed an Investigational New Drug application (IND) with the US Food and Drug Administration as it moves its pipeline into clinical development. The IND is for a Phase I clinical trial for ADCT-301, a novel antibody drug conjugate targeting CD25, a cell-surface antigen, which is over-expressed in many patients with lymphomas. The Phase I clinical trial will commence at four leading oncology centres in the USA, and can expand into two centres in the United Kingdom. The initial up to 58 patient adaptive designed dose-escalation study, will evaluate the tolerability, safety, pharmacokinetics and antitumor activity of ADCT-301 in patients with relapsed or refractory Hodgkin's and Non-Hodgkin's lymphoma. Subject to study results, ADC Therapeutics intends to rapidly expand the numbers of patients in the trial and the participating clinical centres.

ADC Therapeutics Announces Board Appointment

ADC Therapeutics announced expansion of its team as the company's first ADCs enter clinical development. New team members include: Dr. Jay Feingold joins as Chief Medical Officer and Head of Oncology Clinical Development. Dr. Feingold has more than 25 years of industry, academic and medical experience and was most recently Vice President, US Medical Affairs and Chairman Global Medical Affairs Oversight Committee at Daiichi Sankyo. Prior to this, he served as Vice President of Clinical Development, Global Therapy Area Director, Oncology at Wyeth. Dr. Michael Mulkerrin joins as Head of CMC (Chemistry Manufacturing and Control). Dr. Mulkerrin has more than 20 years of industry experience in biologics manufacturing, most recently as Vice President, Process Development and Manufacturing at OncoMed and has had prior senior roles at Abgenix, Amgen and Genentech. Dr. Simon Chivers joins as Head of Toxicology. Dr. Chivers has more than 15 years of industry experience, most recently as Global Head Biologics Safety Assessment and Executive Director at Novartis and has had prior senior roles at AstraZeneca, Syngenta and Quintiles. Mr. Stéphane Henchoz joins as Director of Finance, bringing more than 20 years pharmaceutical industry finance experience, most recently working at Merck Serono.

Similar Private Companies By Industry

Company Name Region
ImmuPharma AG Europe
Tentan AG Europe
AZAD Pharma AG Europe
Chemholding SA Europe
Mepha Pharma AG Europe

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 2, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADC Therapeutics Sarl, please visit www.adctherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.